SPY313.09+2.57 0.83%
DIA259.26+1.95 0.76%
IXIC10,246.01+91.39 0.90%

Audentes Therapeutics Q3 EPS $(1) Beats $(1.07) Estimate

Audentes Therapeutics (NASDAQ:BOLD) reported quarterly losses of $(1) per share which beat the analyst consensus estimate of $(1.07) by 6.54 percent. This is a 3.09 percent decrease over losses of $(0.97) per share from

Benzinga · -

Audentes Therapeutics (NASDAQ:BOLD) reported quarterly losses of $(1) per share which beat the analyst consensus estimate of $(1.07) by 6.54 percent. This is a 3.09 percent decrease over losses of $(0.97) per share from the same period last year.